
NEWS RELEASE

iX Biopharma Named Among Singapore's Fastest Growing Companies 2026

Singapore, 20 January 2026 – iX Biopharma Ltd. (“iX Biopharma” or the “Company”), a specialty pharmaceutical company listed on the Singapore Exchange (SGX), is pleased to announce that it has been recognised as one of **Singapore's Fastest Growing Companies 2026** by *The Straits Times* in collaboration with global research firm Statista.

The annual ranking recognises companies that have demonstrated strong revenue growth and resilience over recent years, underscoring iX Biopharma’s continued business momentum and effective execution of its growth strategy. This is the Company’s third time receiving the award, following earlier recognitions in 2023 and 2024.

The Company’s growth has been driven by its proprietary WaferiX® sublingual drug delivery technology platform. As highlighted in today’s *Straits Times* feature (<https://www.straitstimes.com/business/how-drug-delivery-patent-is-driving-pharmaceutical-company-growth-ix-biopharma>), iX Biopharma is expanding in the United States, focusing on the **longevity and wellness market**, supply via **compounding pharmacy**, and **potential Wafermine collaboration**.

Commenting on the award, Eva Tan, Chief Commercial Officer of iX Biopharma, said: “This recognition reflects the momentum we have built and our confidence in our growth strategies. We are entering our next phase with a capital-light U.S. expansion strategy and the build-out of a proprietary longevity digital platform, positioning the Company for scalable, long-term growth.”

The full list of Singapore’s Fastest Growing Companies 2026 is available on *The Straits Times* website at <https://www.straitstimes.com/fastest-growing-companies-2026>.

Contact for media:

Eva Tan
Chief Commercial Officer
T: +65 6235 3212
E: eva.tan@ixbiopharma.com

Daniel Chow
Director of Business Development
T: +65 6235 2270
E: daniel.chow@ixbiopharma.com